The Biotech Growth Trust PLC - GSK plc to acquire BIOG portfolio company, Nuvalent, Inc.
("BIOG" or the "Company")
GSK plc to acquire BIOG portfolio company, Nuvalent, Inc.
The Company notes the announcement on Tuesday,
Nuvalent is a US-based biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. Its two lead drugs are both under review for marketing approval and are expected to be available to treat non-small cell lung cancer patients that have specific mutations later this year.
The Company's holdings in Nuvalent represented 1.5% of the Company's net asset value ("NAV") at the time of the announcement.
The transaction will be reflected in the Company's NAV as at close of business on Tuesday,
This follows recent acquisitions of portfolio companies Avidity Biosciences, Cidara Therapeutics, Amicus Therapeutics,
To sign up for BIOG updates by email, please click here .
Enquiries:
Public Relations
020 3757 6894
Company Secretary
020 3709 8734
